Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (��losar Luka) .

101 - 110 / 130
Na začetekNa prejšnjo stran45678910111213Na naslednjo stranNa konec
101.
Reproducibility of malignant pleural mesothelioma histopathologic subtyping
Luka Brčić, Gregor Vlačić, Franz Quehenberger, Izidor Kern, 2018, izvirni znanstveni članek

Povzetek: Context. Malignant pleural mesothelioma (MPM) is a rare tumor with poor prognosis. Several studies have analyzed potential prognostic markers, but histologic type remains the single most important prognostic factor. Histologic subtypes of epithelioid MPM seem to have prognostic and therapeutic implications. Interobserver agreement in histologic pattern classification should be high. Objective. To assess interobserver and intraobserver reproducibility in histologic differentiation between the main types of MPMs, and in further subtyping of epithelioid-type mesothelioma. Design. One representative hematoxylin-eosin-stained slide was selected from the archive for each of 200 patients with MPM. They were reviewed independently by 3 pathologists and classified according to the current World Health Organization classification of pleural tumors. After the first round of evaluations, a consensus meeting was organized where problems were addressed and representative images for each histologic category were selected. Two months later, cases were reevaluated by all 3 pathologists. Results. After the first round, overall interobserver agreement for histologic subtyping of mesothelioma was fair (k, 0.36). The agreement was increased to substantial (k, 0.63) in the second round. Improvement was found in interobserver agreement for all types of MPM, and for most epithelioid subtypes. Conclusions. Moderate to substantial agreement in histologic typing and subtyping of MPM can be achieved. However, training with additional clarification of diagnostic criteria, their strict application, and help from consensus-based illustrative images is needed.
Ključne besede: connective and soft tissue neoplasms -- pathology, malignant pleural mesothelioma, histopathology
Objavljeno v DiRROS: 30.11.2020; Ogledov: 5929; Prenosov: 451
URL Povezava na datoteko

102.
NSCLC molecular testing in Central and Eastern European countries
Ales Ryška, Peter Berzinec, Luka Brčić, Tanja Čufer, Rafal Dziadziuszko, Maya Gottfried, Ilona Kovalszky, Włodzimierz Olszewski, Buge Oz, Lukas Plank, József Tímár, 2018, izvirni znanstveni članek

Povzetek: Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines. Methods: A questionnaire about molecular testing and NSCLC management was distributed to relevant specialists in nine CEE countries, and pathologists were asked to provide the results of EGFR and ALK testing over a 1-year period. Results: A very high proportion of lung cancer cases are confirmed histologically/cytologically (75-100%), and molecular testing of NSCLC samples has been established in all evaluated CEE countries in 2014. Most countries follow national or international guidelines on which patients to test for EGFR mutations and ALK rearrangements. In most centers at that time, testing was undertaken on request of the clinician rather than on the preferred reflex basis. Immunohistochemistry, followed by fluorescent in situ hybridization confirmation of positive cases, has been widely adopted for ALK testing in the region. Limited reimbursement is a significant barrier to molecular testing in the region and a disincentive to reflex testing. Multidisciplinary tumor boards are established in most of the countries and centers, with 75-100% of cases being discussed at a multidisciplinary tumor board at specialized centers. Conclusions: Molecular testing is established throughout the CEE region, but improved and unbiased reimbursement remains a major challenge for the future. Increasing the number of patients reviewed by multidisciplinary boards outside of major centers and access to targeted therapy based on the result of molecular testing are other major challenges.
Ključne besede: non-small-cell lung carcinoma, molecular diagnostic techniques, EGFR mutations, ALK rearrangements, Central Europe, Eastern Europe
Objavljeno v DiRROS: 30.11.2020; Ogledov: 1592; Prenosov: 905
.pdf Celotno besedilo (373,86 KB)
Gradivo ima več datotek! Več...

103.
104.
105.
Non-small cell lung cancer in countries of Central and Southeastern Europe : diagnostic procedures and treatment reimbursement surveyed by the Central European Cooperative Oncology Group
Ales Ryška, Rares Buiga, Albena Fakirova, Izidor Kern, Włodzimierz Olszewski, Lukas Plank, Sven Seiwerth, Erika Toth, Eri Zivka, Christiane Thallinger, Christoph Zielinski, Luka Brčić, 2018, izvirni znanstveni članek

Povzetek: This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. Implications for Practice. This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options.
Ključne besede: Non-small cell lung carcinoma -- diagnosis -- economics -- Europe, molecular diagnostic techniques, precision medicine, Central Europe, Southeastern Europe, reimbursement
Objavljeno v DiRROS: 09.11.2020; Ogledov: 1467; Prenosov: 347
URL Povezava na datoteko

106.
107.
Lung cancer biomarker testing : perspective from Europe
Erik Thunnissen, Birgit Weynand, Dalma Udovicic-Gagula, Luka Brčić, Malgorzata Szolkowska, Paul Hofman, Silvana Smojver-Ježek, Sisko Anttila, Fiorella Calabrese, Izidor Kern, 2020, pregledni znanstveni članek

Povzetek: A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Ključne besede: lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing
Objavljeno v DiRROS: 21.09.2020; Ogledov: 1637; Prenosov: 1057
.pdf Celotno besedilo (1,80 MB)
Gradivo ima več datotek! Več...

108.
Conceptual design of a decision support tool for severe accident management in nuclear power plants
Marko Bohanec, Ivan Vrbanić, Ivica Bašič, Klemen Debelak, Luka Štrubelj, 2019, objavljeni znanstveni prispevek na konferenci

Objavljeno v DiRROS: 10.09.2020; Ogledov: 1553; Prenosov: 407
.pdf Celotno besedilo (496,46 KB)

109.
Spremljanje tujerodnih ambrozijskih podlubnikov : tudi doma izdelane pasti so lahko učinkovite
Luka Pajek, Tine Hauptman, Maja Jurc, 2020, izvirni znanstveni članek

Povzetek: Ambrozijske podlubnike uvrščamo med najpomembnejše tujerodne invazivne organizme. Še posebej uspešna pri osvajanju novih območij pa je vrsta Xyosandrus germanus, ki je bila leta 2000 prvič najdena tudi v Sloveniji. Namen naše naloge je bil potrditi razširjenost in ugotoviti velikost populacije X. germanus v revirju Šentvid (KE ZGS Škofljica). Vrsto smo spremljali s pomočjo pasti iz odpadnih plastenk, ki smo jih naredili sami. Postavljene so bile v treh različnih gozdnih sestojih, in sicer smo v vsakem sestoju postavili štiri pasti z različnimi vabami (etanol, denaturiran etanol, kombinacija etanola in %-pinena ter kontrolna past brez vabe), v zbirni posodi je bil konzervans etilen glikol. Pasti smo spremljali osem tednov, v obdobju med 26. 4. 2017 in 20. 6. 2017, jih tedensko praznili, ulov pa determinirali v Laboratoriju za ekološke raziskave - entomologija, Oddelka za gozdarstvo in obnovljive gozdne vire BF. Ujeli smo 11.460 osebkov X. germanus, kar je v skupnem ulovu pomenilo kar 90,09 % celotnega ulova hroščev oziroma 95,30 % celotnega ulova podlubnikov. Tako številčen ulov kaže na to, da je populacija X. germanus na raziskovalnem območju velika. Poleg vrste X. germanus smo potrdili še enega tujerodnega ambrozijskega podlubnika, in sicer vrsto Gnathotrichus materiarius. Naši rezultati kažejo, da ni večjih razlik v učinkovitosti privabljanja vrste X. germanus med testiranimi vabami. Glede na število ujetih osebkov vrste X. germanus pa lahko trdimo, da so tudi doma narejene pasti iz odpadnih plastenk lahko primerno orodje za spremljanje tujerodnih ambrozijskih podlubnikov.
Ključne besede: gozdovi, ambrozijski podlubniki, invazivne tujerodne vrste, Xylosandrus germanus, spremljanje, pasti, vabe, Slovenija
Objavljeno v DiRROS: 09.09.2020; Ogledov: 5474; Prenosov: 1693
URL Povezava na celotno besedilo
Gradivo ima več datotek! Več...

110.
Meritve gostote lesa v slovenskih gozdovih
Luka Krajnc, Polona Hafner, Andreja Vedenik, Jožica Gričar, Primož Simončič, 2020, strokovni članek

Povzetek: V prispevku je predstavljen primer raziskave o variabilnosti kakovosti lesa različnih drevesnih vrst v slovenskih gozdovih. Meritve gostote, ki je eden glavnih pokazateljev kakovosti lesa, bodo služile za izdelavo podatkovne baze za oceno prostorske variabilnosti kakovosti lesa v Sloveniji. Zanesljivih in objektivnih podatkov o kakovosti lesa v naših gozdovih je relativno malo. Takšne baze so na ravni Slovenije izjemno pomembne, saj omogočajo vpogled v kakovost lesa, ki bo v prihodnje na voljo kot surovina na trgu za domačo lesno industrijo. Podobne baze bodo pomembne za izračun količine vezanega ogljika v nadzemni in podzemni biomasi za Slovenijo, hkrati pa bodo zbrani podatki služili tudi kot izhodišče za nadaljnje analize kakovosti lesa, zlasti mehanske lastnosti, ki so ključne pri uporabi lesa za konstrukcijske namene. Lastnosti in razpoložljivost lesa ekonomsko pomembnih drevesnih vrst so osnova za razvoj gozdno-lesne verige glede novih tehnologij, razvoja novih biomaterialov in potenciala rabe lesa različnih kakovosti z optimalnimi izkoristki.
Ključne besede: rezistograf, gostota lesa, kakovost lesa, listavci, iglavci
Objavljeno v DiRROS: 09.08.2020; Ogledov: 1973; Prenosov: 550
.pdf Celotno besedilo (235,34 KB)

Iskanje izvedeno v 0.2 sek.
Na vrh